KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer. PMID 39928262 · Breast Cancer Res Treat · 2025-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Radiotherapy quality assurance for the PEACE 1 trial: An individual case review analysis. PMID 39924002 · Radiother Oncol · 2025-May The record describes a radiotherapy quality assurance sub-study of the PEACE-1 Phase III trial, focusing on protocol compliance for RT plan delineation and dosimetry. It does not report on any time-to-event efficacy endpoints (e.g., OS, PFS) or survival analysis (Kaplan-Meier, HR).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The positive impact of an internet-based post-diagnosis disease management model on patients undergoing opportunistic screening for upper gastrointestinal cancer: A randomized controlled trial. PMID 39919618 · Patient Educ Couns · 2025-May The trial is a randomized controlled trial in oncology patients but does not meet key eligibility criteria: it is not a Phase III or II/III trial, it lacks a drug-containing intervention, and its primary endpoint is not a time-to-event efficacy measure.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Triaging mammography with artificial intelligence: an implementation study. PMID 39881074 · Breast Cancer Res Treat · 2025-May The study is an oncology RCT with original results, but it is not a Phase III/definitive drug trial and its primary endpoints are operational time-to-diagnosis metrics, not time-to-event efficacy endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials. PMID 39848335 · Ann Oncol · 2025-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
An Artificial Intelligence-Digital Pathology Algorithm Predicts Survival After Radical Prostatectomy From the Prostate, Lung, Colorectal, and Ovarian Cancer Trial. PMID 39841869 · J Urol · 2025-May The study is a prognostic/biomarker analysis (AI pathology algorithm) applied to a subset of patients from a randomized screening trial. It does not evaluate a drug-containing intervention in a definitive phase trial with a primary/key secondary time-to-event efficacy endpoint for that intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population. PMID 39805350 · Ann Oncol · 2025-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA). PMID 39732365 · J Thorac Oncol · 2025-May The record is excluded because it is a non-randomized, single-center pilot study, not a randomized Phase III/IIIb or Phase II/III trial as required. While it is an oncology human study with a drug intervention and reports DFS data, the lack of randomization and definitive phase (the study is described as a pilot, and publication types include Phase I/II) makes it ineligible for the Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Evolution of Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials: A Clinical Trial Databank Analysis. PMID 39698868 · United European Gastroenterol J · 2025-May The record is not oncology and does not have a time-to-event efficacy endpoint, making it ineligible for the oncology Kaplan-Meier digitization cohort.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A relook at the relevance of thyroid stimulating hormone and thyroid autoimmunity for pregnancy outcomes: Analyses of randomized control trials data from Pregnancy in Polycystic Ovary Syndrome and Assessment of Multiple Intrauterine Gestations from Ovarian Stimulation. PMID 39672366 · Fertil Steril · 2025-May 未发现恶性肿瘤人群证据。
H L B
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Study on the role of postoperative rehabilitation based on the ERAS concept for patients undergoing pancreaticoduodenectomy: Protocol for a randomized controlled clinical trial. PMID 39642276 · Adv Clin Exp Med · 2025-May The record is a protocol for a randomized controlled trial. It is a study plan, not a formal result report. The trial assesses a postoperative rehabilitation program (non-drug intervention) after pancreaticoduodenectomy for cancer, but the primary endpoint is cardiopulmonary capacity (6-minute walk test), and secondary endpoints are quality of life and recovery metrics, not a time-to-event efficacy endpoint. No drug intervention is present. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Erzhu Jiedu Decoction Granules in Treating Mid-advanced Hepatitis B Virus-Associated Primary Liver Cancer Patients with Pi (Spleen)-Deficiency and Dampness-Heat Syndrome. PMID 39636494 · Chin J Integr Med · 2025-May The study is a randomized oncology trial with a primary time-to-event endpoint (PFS) and reports original results. However, it is excluded because the intervention is a traditional Chinese herbal medicine preparation, not a standard oncology drug as required by the cohort criteria, and the trial phase is not explicitly reported in the metadata to confirm it is Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial. PMID 39632125 · Eur Urol · 2025-May The trial is nonrandomized and compares two non-drug interventions (HIFU vs. radical prostatectomy). It therefore fails two mandatory inclusion criteria: randomized trial design and a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma. PMID 39532185 · J Hepatol · 2025-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Abdominal Noncontrast Computed Tomography Scanning to Screen for Kidney Cancer and Other Abdominal Pathology Within Community-based Computed Tomography Screening for Lung Cancer: Results of the Yorkshire Kidney Screening Trial. PMID 39271419 · Eur Urol · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial. PMID 37183782 · Health Technol Assess · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Prognostic impact of clinical trial eligibility in patients with advanced gastric cancer. PMID 40164709 · Sci Rep · 2025-Mar-31 The record describes a retrospective prognostic study analyzing the impact of eligibility criteria from the CheckMate 649 trial on outcomes in clinical practice. It is not the original trial report with primary or secondary efficacy results. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Whole stomach versus narrow gastric tube reconstruction after esophagectomy for esophageal cancer (ATHLETE trial): study protocol for a randomized controlled trial. PMID 40155976 · Trials · 2025-Mar-29 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Prospective, Randomized, Comparative Study of Myeloablative Fludarabine/Busulfan and Fludarabine/Busulfan/Total Body Irradiation Conditioning in Myeloid Diseases. PMID 40227676 · Cancers (Basel) · 2025-Mar-28 Phase is not explicitly confirmed as Phase III/IIIb or Phase II/III; the study is a prospective randomized trial comparing two drug-containing conditioning regimens (fludarabine/busulfan with or without TBI) for myeloid malignancies, reporting OS and relapse as time-to-event endpoints. However, the phase is not stated in the metadata, and the deterministic review flagged phase evidence as unclear, leading to exclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
PD-1 inhibitors improve the efficacy of transcatheter arterial chemoembolization combined with apatinib in advanced hepatocellular carcinoma: a meta-analysis and trial sequential analysis. PMID 40155828 · BMC Cancer · 2025-Mar-28 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The Effect of Nurse Navigators in Digital Remote Monitoring in Cancer Care: Case Study Using Structural Equation Modeling. PMID 40153795 · J Med Internet Res · 2025-Mar-28 The record describes a Phase III RCT, but the primary endpoint is 'relative dose intensity', not a time-to-event efficacy endpoint. The outcomes analyzed (toxicity, hospitalization, etc.) are not time-to-event efficacy metrics, and no Kaplan-Meier or HR data is reported. Therefore, it does not meet the required time-to-event efficacy endpoint criterion.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A Missing Mechanism of Effect: How People Who Habitually Replot Stories React Differently (Or Not so Differently) to Melanoma Narratives. PMID 39550610 · J Health Commun · 2025-Mar-28 While the study is an oncology-related randomized trial in humans, it is excluded because it is not a drug intervention trial and does not have a primary time-to-event efficacy endpoint. The outcome measured is behavioral intention, not survival or progression metrics.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy - dissection of IO- efficacy in NSCLC by longitudinal tracKing - protocol of a non-randomised, open-label, single-arm, phase II study. PMID 40147985 · BMJ Open · 2025-Mar-27 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Association of energy source with outcomes in en bloc TURB: secondary analysis of a randomized trial. PMID 40146341 · World J Urol · 2025-Mar-27 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial. PMID 40140821 · Mol Cancer · 2025-Mar-26 The record describes a randomized trial in oncology with a drug intervention and a time-to-event endpoint (iDFS), but the trial phase is not specified in the provided metadata as Phase III/IIIb or Phase II/III. Furthermore, the primary endpoint is pCR (a binary endpoint), while iDFS is a secondary endpoint. To be eligible, the trial must be Phase III/IIIb or Phase II/III and must have a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE trial. PMID 40139834 · J Immunother Cancer · 2025-Mar-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Positron emission tomography-adapted therapy for first-line treatment in adults with Hodgkin lymphoma. PMID 40135712 · Cochrane Database Syst Rev · 2025-Mar-26 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial. PMID 40133484 · NPJ Precis Oncol · 2025-Mar-25 The study is a randomized clinical trial in oncology (ovarian cancer) with a drug intervention (chemotherapy) and reports time-to-event endpoints (PFS with HR). However, the abstract explicitly states the primary outcome was Objective Response Rate (ORR), which is not a time-to-event endpoint. The phase (III/IIIb or II/III) is not clearly established in the provided metadata. Therefore, it does not meet all required criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Treatment group-specific inferences in Phase III Randomized Oncology Trials. PMID 40126209 · Acta Oncol · 2025-Mar-24 This is a methodological review analyzing 774 published Phase III oncology trials, not the original result report of a single randomized trial. It lacks a specific drug intervention and does not present a primary time-to-event efficacy endpoint for a single study.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of Cholecalciferol Supplementation on Radiotherapy Outcomes in Advanced Cervical Cancer. PMID 40123110 · Med Sci Monit · 2025-Mar-24 The study is a randomized, oncology, human trial with a drug intervention (cholecalciferol). However, it is not a Phase III trial, and the primary outcome is a categorical response rate (complete response), not a time-to-event endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier or HR analysis. Therefore, it does not meet the eligibility criteria for a KM-digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Assessing the impact of a self-guided digital intervention for fear of cancer recurrence (iConquerFear) in ovarian cancer survivors: a pilot randomised waitlist-controlled trial. PMID 40122804 · BMC Cancer · 2025-Mar-23 The record describes a pilot randomized trial of a digital intervention for fear of cancer recurrence. It is not Phase III/IIIb or Phase II/III, lacks a drug intervention, and does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Therefore, it is not eligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure with preserved ejection fraction. PMID 40121452 · Cardiovasc Diabetol · 2025-Mar-22 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC. PMID 40121197 · Nat Commun · 2025-Mar-22 The report is a preplanned biomarker subgroup analysis of a phase 3 randomized trial, not the primary formal-result report of the trial's overall efficacy.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study. PMID 39889250 · J Clin Oncol · 2025-Mar-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1). PMID 39680823 · J Clin Oncol · 2025-Mar-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT. PMID 39621965 · J Clin Oncol · 2025-Mar-20 The study is a randomized Phase III trial with a drug intervention and reports original results. However, the primary and key secondary endpoints are proportions (complete response rates), not time-to-event outcomes (OS, PFS, DFS, etc.). Therefore, it does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Non-invasive physical plasma for preventing radiation dermatitis in breast cancer: study protocol for a phase 3 randomised double-blind placebo-controlled trial (NIPP-RD III). PMID 40108640 · Trials · 2025-Mar-19 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Evaluation of the androgen receptor in patients with ERα-positive early breast cancer treated with adjuvant tamoxifen ± fluoxymesterone. PMID 40108635 · Breast Cancer Res · 2025-Mar-19 This report is a biomarker subgroup analysis of a randomized trial, not the primary result report of a definitive Phase III/IIIb or Phase II/III trial. The trial phase is not explicitly established in the provided metadata as meeting the required threshold.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study. PMID 40105996 · J Neurol · 2025-Mar-19 未发现恶性肿瘤人群证据。
H L B
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial. PMID 40102973 · Trials · 2025-Mar-19 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Is it beneficial to add laser ablation to curettage in the treatment of pilonidal sinus disease? PMID 40100423 · Lasers Med Sci · 2025-Mar-18 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial. PMID 39665585 · JAMA · 2025-Mar-18 The trial meets oncology, human, randomized, and time-to-event criteria but is excluded because the intervention is non-drug-only (active monitoring vs. surgery/radiation) and the Phase III/IIIb or Phase II/III status is not explicitly established in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Telpegfilgrastim for chemotherapy-induced neutropenia in patients with non-small cell lung cancer: a multicentre, randomized, phase 3 study. PMID 40098083 · BMC Cancer · 2025-Mar-17 The study meets criteria for oncology, human, randomized, phase 3, drug intervention, and original results. However, the primary and secondary endpoints (duration of neutropenia, incidence of febrile neutropenia) are not time-to-event efficacy endpoints (OS, PFS, DFS, etc.) and do not involve Kaplan-Meier analysis or hazard ratios. The study evaluates supportive care efficacy (neutropenia management) in an oncology population, which is excluded from the cohort's scope.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Suppressive effects of deep balanced anesthesia on cellular immunity and protein expression: a randomized-controlled pilot study. PMID 40097954 · BMC Anesthesiol · 2025-Mar-17 Study is a randomized pilot study on anesthesia effects on immune function, not an oncology drug trial with time-to-event efficacy endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial). PMID 39836408 · Clin Cancer Res · 2025-Mar-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
MAPK Pathway-Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial. PMID 39836372 · Clin Cancer Res · 2025-Mar-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts. PMID 39820657 · Clin Cancer Res · 2025-Mar-17 This is a biomarker correlative study from two randomized Phase II trials (STOMP and ORIOLE) evaluating stereotactic ablative radiotherapy (SABR), not a drug-containing intervention. The primary analysis is biomarker-focused and does not represent the original primary efficacy report of the trials.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2- Metastatic Breast Cancer. PMID 40136373 · Curr Oncol · 2025-Mar-15 While the study is from a randomized Phase III trial (TROPiCS-02) with a drug intervention and original results for OS/PFS, this specific publication is a Q-TWiST analysis. It is a secondary, patient-preference and quality-of-life integrated analysis, not the primary or key secondary report of the time-to-event efficacy endpoint (OS, PFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase 2 Trial of Consolidative Stereotactic Body Radiation Therapy in Patients With Metastatic Oncogene-driven Non-small Cell Lung Carcinoma Treated With Tyrosine Kinase Inhibitors. PMID 39577475 · Int J Radiat Oncol Biol Phys · 2025-Mar-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase 2 Trial. PMID 39486645 · Int J Radiat Oncol Biol Phys · 2025-Mar-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -